Two interesting bids on the billboard Genzyme and Ascendis Pharma

-
Courtesy Bloomberg



Sanofi-Aventis may begin a hostile bid for Genzyme Corp. should the U.S. biotechnology company resist a takeover approach, analysts at Citigroup Inc. said.
No other bidder is likely to emerge for Cambridge, Massachusetts-based Genzyme, and Sanofi will probably succeed in acquiring the company for $74 to $77 a share, Citigroup analysts Mark Dainty and Yaron Werber wrote in a report to clients today. Genzyme is worth $70 a share based on estimated cash flow, and Sanofi would benefit from as much as $5.50 a share of synergies in an acquisition, they said.
Investors in Genzyme say Paris-based Sanofi may have to pay at least $80 a share, or $21.3 billion, to acquire the maker of drugs that fight genetic diseases. Sanofi Chief Executive Officer Chris Viehbacher has support from his board to offer as much as $70 a share, or about $18.7 billion, and is preparing a formal offer letter, three people familiar with the situation said last week.
Novo Nordisk A/S, Novartis AG’S Sandoz and Eli Lilly & Co. are among bidders for Ascendis Pharma A/S of Denmark,  
The Copenhagen-based health-care company received offers of about $400 million, said the person, who declined to be identified because the process isn’t public. Ascendis may choose a final bidder by early September.


Ascendis has a technology that allows drugs to be released into the body in a controlled way over time, according to its website. The company focuses on hormone-related disorders and is developing a human growth hormone that can be taken once a week. It’s also developing new formulations of approved medicines and products for central nervous system and infectious diseases, according to the website.

Share |

Comments

Post a Comment

Popular posts from this blog

Sequence Analysis is still sexy:Dual Descriptor Method for Biological Sequence Analysis

-
The emergence of “Systems Biology” in recent years highlights the systematic viewpoint of bio-system modeling. Building on such a background, Dual Descriptor Method, a generic methodology for biological sequence analysis is proposed. From a systematic perspective, Dual Descriptor is defined as a two element set of Composition Weight Map and Position Weight Function which aim at reflecting the composition and permutation information of a sequence. An alternate training algorithm is provided to get an optimum description of the building patterns of the sequences. In this paper , dual descriptor method has been applied to the analysis of two typical problems of molecular biology: gene identification and the prediction of protein function. Satisfactory and insightful results are achieved. Owing to the generality of this methodology, dual descriptor method has wide application perspective for many problems of pattern recognition, especially those involved in “Systems Biology”. Be a part of
Read more

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

-
Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. &quo
Read more

List of Cheminformatics Companies & Institutions

-
Accelrys ACD/Labs (Advanced Chemistry Development, Inc.) Afferent Systems Inc. Agilent Technologies Aureus Pharma Barnard Chemical Information Ltd. (John Barnard and Geoff Downs) SEE: digital chemistry Bio-Rad Laboratories BioReason BioSolveIT BlueObelisk.org Bruker Daltonics Inc. Cambridge Crystallographic Data Centre CambridgeSoft Corporation CARB Center for Advanced Research in Biotechnology (NIST/University of Maryland) Cengent Therapeutics (Genes to Leads). Acquired by Inncardio, Inc. Center for Molecular Modeling (NIH) Centre for Molecular and Biomolecular Informatics CMBI (formerly: CAOS/CAMM: Dutch National Center for Computer-Assisted Chemistry and Molecular Modelling) Cerep ChemAxon ChemDiv, Inc. (Chemical Diversity) Chemical Abstracts Service Chemical Computing Group, Inc. Chemical Simulations Group ChemInnovation Software ChemNavigator ChemSW (Chemistry Software for Windows, formerly: WindowChem) Chenomx Inc. CIS Chemical Information System CombiChem.net CompuChem C
Read more